Fig. 8
A Combination therapy using Regorafenib 40µM and increasing level of Quercetin could significantly down-regulate β1 integrin expression in resistant colon cancer cells (p < 0.01); B There was a significant difference not only between the Regorafenib subgroups but also between the Regorafenib group and untreated state (p < 0.05); C There was a significant difference between the subgroups of Quercetin and the QDMP/siRNA (P < 0.01). In the Quercetin group, a decrease in β1 integrin expression in resistant cells was significantly higher in IC30 than IC10, IC30 than IC20 (P < 0.01), however, a significant decrease was not observed between IC20 and IC10 (P = 0.09). While, in the QDMP/siRNA group, inter-group comparison of treatment at all doses (IC30, IC20, and IC10) represented a significant decrease in β1 integrin expression; D No significant relationship was observed in siRNA subgroups. Except, NP/siRNA with untreated state (p = 0.02).NP: nanoparticle without drug. R: Regorafenib; Q: Quercetin; RDMP: Reg/DDAB mPEG-PCL nanoparticles; QDMP: Q/DDAB mPEG-PCL nanoparticles; siRNA; small interfering RNA